India's Gland Pharma beats quarterly profit view on strong Europe, US sales

Gland Pharma

10/08/2026 12:05

Aug 10 (Reuters) - India's Gland Pharma GLAD.NS reported a bigger-than-expected first-quarter profit on Monday, boosted by strong sales in its key European and U.S. markets.
The Hyderabad-based company reported a consolidated net profit of 3.17 billion rupees ($33.3 million) for the quarter ended June 30, from 2.15 billion rupees a year earlier.
That also beat analysts' average estimate of 2.89 billion rupees, per data compiled by LSEG.

Here are some more details:
U.S. sales, which make up more than half of the total, rose 32%, while the Europe business posted a 20% rise. 
Gland Pharma's results have been consistently boosted since a recovery in production at its Cenexi units in France and Belgium in late 2025.
Disruption at these units had hurt the drugmaker's results throughout most of last year.
Overall revenue rose 20% to 18 billion rupees, also beating estimates of 17.33 billion rupees.
Gland Pharma and several of its Indian generic drugmaker peers that derive a large share of their revenue from the U.S. have been grappling with limited pricing power amid stiff competition in that market.
Larger rivals Cipla CIPL.NS and Dr Reddy's REDY.NS also reported subdued U.S. sales during the quarter.


($1 = 95.3000 Indian rupees)

 (Reporting by Kashish Tandon in Bengaluru; Editing by Ronojoy Mazumdar)
 ((Kashish.Tandon@thomsonreuters.com; 8800437922;))